"10.1371_journal.pone.0126194","plos one","2015-05-04T00:00:00Z","Angelique Riepsamen; Lindsay Wu; Laurin Lau; Dave Listijono; William Ledger; David Sinclair; Hayden Homer","School of Womens & Childrens Health, University of New South Wales, Sydney, New South Wales, Australia; School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia; Genetics Department, Harvard Medical School, Boston, Massachusetts, United States of America; Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, Massachusetts, United States of America","Conceived and designed the experiments: HH AR LW. Performed the experiments: HH AR LL DL. Analyzed the data: HH AR LL DL. Contributed reagents/materials/analysis tools: HH WL LW DS. Wrote the paper: HH AR LW WL DS. Provided expert knowledge on sirtuin-related and NAM/NAD pathways: LW DS. Provided funding support and facilitated acquisition of lab space and equipment: WL.","LW and DS are non-paid directors and shareholders of MetroBiotech NSW Pty Ltd, whose patents concern the use of NAD+ elevating agents to treat disease and are unrelated to nicotinamide (WO2014059034 and Australian provisional patent application number 2013904415). DS is a shareholder and paid consultant to GlaxoSmithKline, a shareholder and scientific advisor to OvaScience, and a shareholder and director to MetroBiotech NSW Pty Ltd and MetroBiotech LLC. None of these interests relate to the present work, use of nicotinamide in oocytes. The authors confirm that they have no restrictions on the sharing of data or materials related to this work. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","05","Angelique Riepsamen","AR",7,TRUE,3,4,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
